[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353153-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-353153-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","activation-of-tumor-specific-cd8-t-cells-prior-to-radiopharmaceutical-therapy-improves-antitumor-response","Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response","","Radiopharmaceutical therapy (RPT) delivers systemic radiation and can reshape the tumor immune microenvironment, but radiosensitivity of tumor-infiltrating lymphocytes may depend on the treatment order. Using E.G7-OVA and TRAMP-C1 models with 90Y-NM600, the study tests naïve versus activated OT-I CD8+ T cells given before or after RPT. Results show enhanced antitumor efficacy when CD8+ T cells are activated prior to RPT, with increased tumor-infiltrating antigen-specific effectors and slowed growth.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/activation-of-tumor-specific-cd8-t-cells-prior-to-radiopharmaceutical-therapy-improves-antitumor-response/353153/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/activation-of-tumor-specific-cd8-t-cells-prior-to-radiopharmaceutical-therapy-improves-antitumor-response/353153.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research question of the study?","Question",{"text":63,"@type":64},"How the timing of tumor-specific CD8+ T cell activation relative to radiopharmaceutical therapy (RPT) affects antitumor outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the key findings about treatment sequence?",{"text":68,"@type":64},"Antitumor efficacy improved when OT-I CD8+ T cells were present and activated before 90Y-NM600, with increased frequencies of tumor-infiltrating antigen-specific effector memory CD8+ T cells and effector molecule production. Similar improvements were observed in the TRAMP-C1 model using tumor antigen-specific vaccination prior to RPT.",{"name":70,"@type":61,"acceptedAnswer":71},"How did interferon signaling contribute to the observed tumor growth delay?",{"text":72,"@type":64},"Blockade of type I interferon, but not upstream inhibition of stimulator of interferon genes, eliminated the tumor growth delay from the combination treatment.",{"name":74,"@type":61,"acceptedAnswer":75},"What does the study suggest for combining RPT with T-cell activating therapies?",{"text":76,"@type":64},"Tumor-specific CD8+ T cells may need to be present and activated before RPT to enhance antitumor effects, and the impacts of RPT on tumor-infiltrating CD8+ T cells should be considered when designing combination sequences.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},353153,1790194440,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Open access Original research  \n Activation of tumor-specific CD8+ T  \ncells prior to radiopharmaceutical therapy improves antitumor response  \nDaeun Shim  , Colette Mouton, Jena E Moseman  , Hansel Comas Rojas, Donghwan Jeon, Malick B Idrissou, Reinier Hernandez, Jamey P Weichert, Douglas G McNeel   \nTo cite: Shim D, Mouton C, Moseman JE, et al. Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response. Journal for ImmunoTherapy of Cancer 2026;14:e015261 . doi:10 . 1136/ jitc-2026-015261  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2026-015261](jitc-2026-015261)) .  \nAccepted 03 June 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA  \nCorrespondence to  \nDr Douglas G McNeel; [dm3@medicine.wisc.edu](dm3@medicine.wisc.edu)  \nABSTRACT  \nBackground Radiopharmaceutical therapy (RPT) delivers radiation systemically, enabling the treatment of metastatic cancers. Beyond killing tumor cells, RPT can modulate the tumor immune microenvironment.  \nWith RPTs and immunotherapies already approved or in development for prostate cancer, many preclinical and clinical studies are evaluating their use in combination. However, due to the radiosensitivity of tumor-infiltrating lymphocytes, further studies are needed to determine the effects of RPT on these cells to better inform the sequence of immunotherapies that activate T cells when given with RPT.  \nMethods E.G7-OVA tumor-bearing mice received naïve or activated OT-I CD8+T cells prior to or following the administration of RPT using 90Y-NM600 . Changes in tumor growth were monitored, and tumor-infiltrating lymphocytes were evaluated for phenotypic and functional markers. The murine prostate tumor model TRAMP-C1 was used to evaluate this approach using tumor antigen-specific vaccination with 90Y-NM600 .  \nResults Antitumor efficacy was improved if OT-I CD8+T cells were present and activated prior to 90Y-NM600 administration than if the cells were delivered after RPT. Similarly, in vivo activation of adoptively transferred OT-ICD8+T cells, using ovalbumin (OVA)-specific vaccination, prior to RPT slowed tumor growth and increased the frequency of tumor-infiltrating OVA257-264-specific CD8+T cells with effector memory phenotype and effector molecule production. Blockade of type I interferon, but not the upstream inhibition of stimulator of interferon genes, abrogated tumor growth delay resulting from the combination treatment. Tumor antigen-specific vaccination prior to 90Y-NM600 administration similarly improved antitumor outcomes in the TRAMP-C1 tumor model. Conclusions Our study suggests that tumor-specific CD8+T cells need to be present and activated prior to RPT to enhance antitumor outcomes. This study highlights the importance of considering the effects of RPT on tumorinfiltrating CD8+T cells when combining other T-cell activating therapies with RPT, as they may similarly display sequence-dependent antitumor outcomes.  \nBACKGROUND  \nRadiation remains a central component of cancer therapy, used in the treatment of  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Radiopharmaceutical therapy (RPT) can modulate the tumor immune microenvironment. Combining RPT with immunotherapy can enhance antitumor outcomes.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study evaluated the effect of a pan-cancer targeting RPT, 90Y-NM600, on tumor-specific CD8+T cells to inform the timing of T cell-activating therapy relative to RPT.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ RPT agents and immunotherapies that can activate T cells are approved for many human cancer types. Our studies suggest that the sequence of these therapies ","cbCaif119dgsU83z","https://ap.wps.com/l/cbCaif119dgsU83z","pdf",2788243,15,"English","## Abstract\n## Background\n## What is already known on this topic\n## What this study adds\n## How this study might affect research, practice or policy","[{\"question\":\"What is the main research question of the study?\",\"answer\":\"How the timing of tumor-specific CD8+ T cell activation relative to radiopharmaceutical therapy (RPT) affects antitumor outcomes.\"},{\"question\":\"What were the key findings about treatment sequence?\",\"answer\":\"Antitumor efficacy improved when OT-I CD8+ T cells were present and activated before 90Y-NM600, with increased frequencies of tumor-infiltrating antigen-specific effector memory CD8+ T cells and effector molecule production. Similar improvements were observed in the TRAMP-C1 model using tumor antigen-specific vaccination prior to RPT.\"},{\"question\":\"How did interferon signaling contribute to the observed tumor growth delay?\",\"answer\":\"Blockade of type I interferon, but not upstream inhibition of stimulator of interferon genes, eliminated the tumor growth delay from the combination treatment.\"},{\"question\":\"What does the study suggest for combining RPT with T-cell activating therapies?\",\"answer\":\"Tumor-specific CD8+ T cells may need to be present and activated before RPT to enhance antitumor effects, and the impacts of RPT on tumor-infiltrating CD8+ T cells should be considered when designing combination sequences.\"}]","Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response | PDF",1790103320,38,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19b942260f90c48f68a40ca0f5df70a6.webp",983,1310,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8369ba4f6d00adbd285a625b2652d08.webp",982,1309,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8fd2254298b715399ed95fb11e87ae3.webp",981,1308,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bfd94c57f540f74294a53df666fb8af.webp",980,1306]